MétaCan
Menu
Back to cohort
Record W4409517327 · doi:10.1002/alz.14587

The CentiMarker project: Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretation

2025· article· en· W4409517327 on OpenAlexfundno aff
Guoqiao Wang, Yan Li, Chengjie Xiong, Yuchen Cao, Suzanne E. Schindler, Eric McDade, Kaj Blennow, Oskar Hansson, Jeffrey L. Dage, Clifford R. Jack, Charlotte E. Teunissen, Leslie M. Shaw, Henrik Zetterberg, Laura Ibáñez, Jigyasha Timsina, Carlos Cruchaga

Bibliographic record

VenueAlzheimer s & Dementia · 2025
Typearticle
Languageen
FieldMedicine
TopicDementia and Cognitive Impairment Research
Canadian institutionsnot available
FundersInstituto de Salud Carlos IIINational Institutes of HealthGenentechFleniDeutsches Zentrum für Neurodegenerative ErkrankungenEisaiKorea Health Industry Development InstituteNational Institute of Biomedical Imaging and BioengineeringCanadian Institutes of Health ResearchGHR FoundationJapan Agency for Medical Research and DevelopmentMinistry of Science and ICT, South KoreaBiogenBioClinicaEli Lilly and CompanyU.S. Department of DefenseAlzheimer's Disease Neuroimaging InitiativeAvid RadiopharmaceuticalsF. Hoffmann-La RocheKorea Dementia Research CenterBristol-Myers SquibbNational Institute on AgingAlzheimer's AssociationFoundation for the National Institutes of Health
KeywordsBiomarkerDiseaseMetric (unit)MedicineStandardizationScale (ratio)Biomarker discoveryBioinformaticsPathologyComputer scienceBiologyProteomicsGenetics

Abstract

fetched live from OpenAlex

INTRODUCTION: Biomarkers play a crucial role in understanding Alzheimer's disease (AD) pathogenesis and treatment effects. However, comparing biomarker measures without standardization and appreciating their magnitude relative to the disease can be challenging. METHODS: To address this issue, we propose the CentiMarker approach, similar to Centiloid, which provides a standardized scale between normal (0) and nearly maximum abnormal AD (100) ranges. We applied this scale to cerebrospinal fluid (CSF) biomarkers in dominantly inherited AD and sporadic AD cohorts. RESULTS: CentiMarkers facilitated the interpretation of disease abnormality, demonstrating comparable changes and distributions of AD biomarkers across disease stages. CentiMarkers make the treatment effect more comparable than their original scales across various biomarkers. DISCUSSION: The versatility of CentiMarkers makes it a valuable tool for standardized biomarker comparison in AD research, enabling informed cross-study comparisons and contributing to accelerated therapeutic development. Adoption of the CentiMarker scale could enhance biomarker reporting and advance our understanding of AD. HIGHLIGHTS: Comparing fluid biomarkers without appreciating their magnitude relative to the disease can be challenging. We propose a CentiMarker metric to standardize biomarker measures from normal (0) and nearly maximum abnormal AD (100) ranges. CentiMarkers make the treatment effect more comparable across various biomarkers than when using the original scales.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.072
metaresearch head score (Gemma)0.138
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Methods · Consensus signal: Methods
Teacher disagreement score0.072
Threshold uncertainty score0.381

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0720.138
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0070.004
Science and technology studies0.0010.003
Scholarly communication0.0060.003
Open science0.0030.009
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0050.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.038
GPT teacher head0.370
Teacher spread0.332 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreMethods

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & DementiaSame topicDementia and Cognitive Impairment ResearchFrench-language works237,207